Literature DB >> 22142353

Renal denervation revisited: promising treatment for resistant hypertension?

Debbie L Cohen1, Raymond R Townsend.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22142353      PMCID： PMC8816430          DOI： 10.1111/j.1751-7176.2011.00563.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  10 in total

1.  Splanchnicectomy for essential hypertension; results in 1,266 cases.

Authors:  R H SMITHWICK; J E THOMPSON
Journal:  J Am Med Assoc       Date:  1953-08-15

2.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

3.  The effects of splanchnicectomy on the blood pressure in hypertension; a controlled study.

Authors:  S W HOOBLER; J T MANNING; W G PAINE; S G McCLELLAN; P O HELCHER; H RENFERT; M M PEET; E A KAHN
Journal:  Circulation       Date:  1951-08       Impact factor: 29.690

Review 4.  Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept.

Authors:  Markus P Schlaich; Paul A Sobotka; Henry Krum; Robert Whitbourn; Anthony Walton; Murray D Esler
Journal:  Hypertension       Date:  2009-10-12       Impact factor: 10.190

5.  Renal Sympathectomy: Its Scope and Limitations: (Section of Urology).

Authors:  S H Harris
Journal:  Proc R Soc Med       Date:  1935-09

6.  Sympathetic nerve activity in end-stage renal disease.

Authors:  Martin Hausberg; Markus Kosch; Patrick Harmelink; Michael Barenbrock; Helge Hohage; Klaus Kisters; Karl Heinz Dietl; Karl Heinz Rahn
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

7.  Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea.

Authors:  Adam Witkowski; Aleksander Prejbisz; Elżbieta Florczak; Jacek Kądziela; Paweł Śliwiński; Przemysław Bieleń; Ilona Michałowska; Marek Kabat; Ewa Warchoł; Magdalena Januszewicz; Krzysztof Narkiewicz; Virend K Somers; Paul A Sobotka; Andrzej Januszewicz
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

8.  Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.

Authors: 
Journal:  Hypertension       Date:  2011-03-14       Impact factor: 10.190

9.  Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers.

Authors:  Ulla C Kopp; Michael Z Cicha; Lori A Smith; Jan Mulder; Tomas Hökfelt
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-08-15       Impact factor: 3.619

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321
  10 in total
  3 in total

Review 1.  Thoracic sympathectomy: a review of current indications.

Authors:  Moshe Hashmonai; Alan E P Cameron; Peter B Licht; Chris Hensman; Christoph H Schick
Journal:  Surg Endosc       Date:  2015-06-27       Impact factor: 4.584

Review 2.  Exploring issues in difficult-to-treat hypertension.

Authors:  Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-10-30       Impact factor: 3.738

Review 3.  Renal denervation for treating resistant hypertension: current evidence and future insights from a global perspective.

Authors:  Y Castro Torres; Richard E Katholi
Journal:  Int J Hypertens       Date:  2013-11-27       Impact factor: 2.420
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.